Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Does Extraesophageal Reflux Support the Development of Lung Adenocarcinoma? Analysis of Pepsin in Bronchoalveolar Lavage in Non-Smoker Patients

P. Zemanova, M. Vocka, Z. Vanickova, F. Liska, L. Krizova, J. Kalab, J. Votruba

. 2024 ; 16 (15) : . [pub] 20240728

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24018151

Grant support
RVO Ministry of Health of the Czech Republic
COOPERATIO, Oncology and Haematology Charles University
BBMRI_CZ LM2023033 European Regional Development Fund
EF16_013/0001674 European Regional Development Fund
LX22NPO5104 National Institute for Research of Metabolic and Cardiovascular Diseases - EXCELES

The significance of extraesophageal reflux as a risk factor in lung adenocarcinoma has been understudied. In this study, we investigated whether extraesophageal reflux leads to higher pepsin concentrations in bronchoalveolar lavage (BAL) in patients with lung adenocarcinoma compared to controls. Subjects were recruited from non-smoker patients (lifelong non-smokers and ex-smokers with more than 5 years of non-smoking history) who had undergone bronchoscopy due to pulmonary abnormalities on a CT scan and met the inclusion criteria. Based on histological verification of the lung process, the patients were divided into three groups: (1) lung adenocarcinoma, (2) pulmonary metastases, and (3) lung sarcoidosis. Lung adenocarcinoma cases were further categorized as central or peripheral. BAL samples collected during bronchoscopy were quantitatively analyzed by enzyme-linked immunosorbent assay (ELISA) to measure pepsin levels. No statistically significant difference in pepsin concentration was observed between the lung adenocarcinoma group and control groups (p = 0.135). After excluding hemorrhagic BAL samples, the pepsin concentration was significantly the lowest in patients with lung adenocarcinoma (p = 0.023) compared to the control groups. The results of the study do not support the hypothesis of a higher occurrence of extraesophageal reflux (evaluated as the amount of pepsin in BAL) in non-smoker patients with lung adenocarcinoma.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018151
003      
CZ-PrNML
005      
20241016081947.0
007      
ta
008      
241008s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers16152687 $2 doi
035    __
$a (PubMed)39123415
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Zemanova, Petra $u First Clinic of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic $u Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, Prague 2, 12808 Prague, Czech Republic
245    10
$a Does Extraesophageal Reflux Support the Development of Lung Adenocarcinoma? Analysis of Pepsin in Bronchoalveolar Lavage in Non-Smoker Patients / $c P. Zemanova, M. Vocka, Z. Vanickova, F. Liska, L. Krizova, J. Kalab, J. Votruba
520    9_
$a The significance of extraesophageal reflux as a risk factor in lung adenocarcinoma has been understudied. In this study, we investigated whether extraesophageal reflux leads to higher pepsin concentrations in bronchoalveolar lavage (BAL) in patients with lung adenocarcinoma compared to controls. Subjects were recruited from non-smoker patients (lifelong non-smokers and ex-smokers with more than 5 years of non-smoking history) who had undergone bronchoscopy due to pulmonary abnormalities on a CT scan and met the inclusion criteria. Based on histological verification of the lung process, the patients were divided into three groups: (1) lung adenocarcinoma, (2) pulmonary metastases, and (3) lung sarcoidosis. Lung adenocarcinoma cases were further categorized as central or peripheral. BAL samples collected during bronchoscopy were quantitatively analyzed by enzyme-linked immunosorbent assay (ELISA) to measure pepsin levels. No statistically significant difference in pepsin concentration was observed between the lung adenocarcinoma group and control groups (p = 0.135). After excluding hemorrhagic BAL samples, the pepsin concentration was significantly the lowest in patients with lung adenocarcinoma (p = 0.023) compared to the control groups. The results of the study do not support the hypothesis of a higher occurrence of extraesophageal reflux (evaluated as the amount of pepsin in BAL) in non-smoker patients with lung adenocarcinoma.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vocka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, Prague 2, 12808 Prague, Czech Republic $1 https://orcid.org/000000029386657X $7 xx0181880
700    1_
$a Vanickova, Zdislava $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic
700    1_
$a Liska, Frantisek $u Institute of Biology and Medical Genetics, Purkyne Institute, First Faculty of Medicine, Charles University in Prague, Albertov 4, 12800 Prague, Czech Republic
700    1_
$a Krizova, Ludmila $u Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, Prague 2, 12808 Prague, Czech Republic
700    1_
$a Kalab, Josef $u First Clinic of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic $1 https://orcid.org/0009000306413068
700    1_
$a Votruba, Jiri $u First Clinic of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, U Nemocnice 2, 12808 Prague, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 16, č. 15 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39123415 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081943 $b ABA008
999    __
$a ok $b bmc $g 2196476 $s 1230102
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 16 $c 15 $e 20240728 $i 2072-6694 $m Cancers $n Cancers (Basel) $x MED00173178
GRA    __
$a RVO $p Ministry of Health of the Czech Republic
GRA    __
$a COOPERATIO, Oncology and Haematology $p Charles University
GRA    __
$a BBMRI_CZ LM2023033 $p European Regional Development Fund
GRA    __
$a EF16_013/0001674 $p European Regional Development Fund
GRA    __
$a LX22NPO5104 $p National Institute for Research of Metabolic and Cardiovascular Diseases - EXCELES
LZP    __
$a Pubmed-20241008

Find record

Citation metrics

Archiving options